Korro Bio, INC Form 4 insider transactions

Paul Edward Walker, a director and 10% owner of Korro Bio, Inc., through an affiliated entity, acquired additional common stock and pre-funded warrants from the issuer.

A director and 10% owner of Korro Bio, Inc. acquired over 450,000 shares and pre-funded warrants through an indirect holding, signaling increased confidence.

Korro Bio's President and CEO, Ram Aiyar, reported the acquisition of 40,000 restricted stock units and options for 80,000 shares of common stock.

Korro Bio's Chief Scientific Officer, Vincent Loic A, was granted 35,000 stock options with a strike price of $13.05, vesting over 48 months.

Korro Bio's Senior Vice President of Finance, Oliver Dolan, was granted 15,000 stock options with an exercise price of $13.05.

Korro Bio's General Counsel, Jeffrey Cerio, was granted 23,000 stock options with an exercise price of $13.05, vesting over four years.

Korro Bio's Chief Operating Officer, Todd Chappell, was granted 20,132 restricted stock units vesting over two dates in 2026.

Korro Bio's Chief Scientific Officer, Vincent Loic A, was granted 21,715 restricted stock units vesting in 2026.

Korro Bio's General Counsel, Jeffrey Cerio, was granted 41,902 restricted stock units (RSUs) that will vest in two tranches in 2026.

Korro Bio, Inc. (KRRO) Senior Vice President of Finance, Oliver Dolan, was granted 21,482 restricted stock units (RSUs) under the company's 2023 Stock Option and Incentive Plan.

Korro Bio, Inc. announced that Director and 10% Owner Ali Behbahani was granted 6,010 stock options with an exercise price of $14.87, vesting on the earlier of one year from the grant date or the next annual meeting.

Korro Bio, Inc. director Rachel Meyers was granted 6,010 stock options with an exercise price of $14.87, vesting over one year or by the next annual meeting.

Korro Bio, Inc. Director Nessan Bermingham was granted 6,010 stock options with an exercise price of $14.87 per share, vesting on the earlier of the one-year anniversary of the grant or the next annual stockholders' meeting.

Korro Bio, Inc. (KRRO) has reported that Director Katharine Knobil was granted 6,010 stock options with an exercise price of $14.87 per share, vesting on the earlier of one year from the grant date or the next annual stockholders' meeting.

Korro Bio, Inc. Director Jean-Francois Formela was granted 6,010 stock options with an exercise price of $14.87, vesting on the earlier of one year or the next annual meeting, aligning his interests with long-term shareholder value.

Korro Bio, Inc. Director Timothy R. Pearson was granted 6,010 stock options with an exercise price of $14.87, vesting on the earlier of one year from the grant date or the next annual meeting of stockholders.

Oliver Dolan, Senior Vice President of Finance at Korro Bio, Inc., reports the acquisition of stock options for 20,000 shares on April 1, 2025.

Loic A. Vincent, Chief Scientific Officer of Korro Bio, Inc., reports the acquisition of stock options for 70,000 shares on April 1, 2025.

Jeffrey Cerio, General Counsel of Korro Bio, Inc., reports the acquisition of stock options.

Vineet Agarwal, CFO of Korro Bio, Inc., reports the acquisition of 30,000 stock options on February 3, 2025.

Korro Bio's CEO, Ram Aiyar, was granted stock options for 100,000 shares on February 3, 2025, according to a Form 4 filing.

Todd Chappell, Chief Operating Officer of Korro Bio, Inc., reports the acquisition of stock options.

Chief Medical Officer of Korro Bio, Olukemi Olugemo, reports the acquisition of stock options and grants a limited power of attorney for SEC filings.

Korro Bio's Chief Financial Officer, Vineet Agarwal, executed a pre-planned sale of 800 shares of common stock and exercised a stock option for 800 shares at a price of $11.68 per share.

Vineet Agarwal, CFO of Korro Bio, Inc., sold shares of common stock on October 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Jeffrey Cerio, General Counsel of Korro Bio, Inc., acquired 40,000 stock options on September 3, 2024, at an exercise price of $44.37.

Director Katharine Knobil acquired stock options for 9,041 shares of Korro Bio, Inc. on August 26, 2024.

Director Ali Behbahani reports the acquisition of stock options in Korro Bio, Inc.

Director Jean Francois Formela of Korro Bio, Inc. reports the acquisition of stock options.

Director Rachel Meyers reports acquisition of stock options in Korro Bio, Inc.